Skip to main content
HeartCited

Heart Failure
Heart Failure

Prevalência: 6.7 million US adults; prevalence increases with age (10% in adults >65)

<\/script>\n
`; }, get iframeSnippet() { const domain = 'heartcited.com'; const params = 'condition\u003Dheart\u002Dfailure'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Evidence-Ranked Ingredients

About

{# Filter order is load-bearing: escape (untrusted text) -> linebreaks (paragraphs) -> paper anchors (internal /papers/ links) -> glossary (never links inside an existing ). #}

A failing heart is not primarily a weak muscle but an energy-starved one. Myocardial tissue consumes more adenosine triphosphate per gram than any other organ, and in heart failure the machinery that regenerates it works less efficiently, which is the observation that has kept mitochondrial cofactors in the research literature for four decades. The clinical syndrome affects 6.7 million US adults and about 10 percent of those over 65, and presents as breathlessness on exertion and later at rest, orthopnoea, paroxysmal nocturnal dyspnoea, peripheral oedema, fatigue and exercise intolerance.

Seven ingredients are graded against this condition, on 42 studies and 8,650 participants. Two reach Grade B, two Grade C and three Grade D.

Coenzyme Q10 has the longest history of the group and holds Grade B on 15 studies and 1,500 participants. It is an obligatory electron carrier in the respiratory chain and a lipid-soluble antioxidant, and myocardial concentrations fall as functional class worsens. Reviews specific to heart failure have assessed both the mechanistic rationale and the trial evidence [1], including sceptical appraisals of whether the endpoint data justify the mechanistic enthusiasm [2]. Formulation is a live issue, since the reduced form, ubiquinol, and the oxidised form, ubiquinone, differ in absorption, and the comparison has been examined directly [3]. A second consideration recurs in this population: statin therapy lowers circulating coenzyme Q10 as a consequence of the same enzymatic inhibition that lowers cholesterol.

Hawthorn holds the other Grade B rating, on 14 studies and 3,800 participants, the largest study-and-participant combination for any botanical on the page. Its extracts contain oligomeric procyanidins and flavonoids, and the trials have generally used standardised preparations with symptom-based and exercise-capacity endpoints.

Vitamin D is graded C with a mixed direction on 6 studies and 3,000 participants. Low vitamin D status is common in heart failure, but the causal direction is contested, since reduced outdoor activity is a consequence of the syndrome as well as a candidate contributor to it. Reviews of vitamin supplementation in this population have addressed that ambiguity explicitly [4]. Taurine completes the Grade C tier on 4 studies and 200 participants, supported by its role in myocardial calcium handling.

The three Grade D entries illustrate the range within a single grade. L-arginine has 3 studies, 150 participants and a mixed direction. NMN and PQQ are recorded with zero studies and zero participants against this endpoint: their inclusion rests on mechanistic reasoning about mitochondrial biogenesis and NAD metabolism, not on trial data, and the grade states as much.

Heart failure is also the cardiovascular condition where interactions carry the greatest consequence, because standard therapy involves diuretics, renin-angiotensin blockade and rhythm-active drugs simultaneously. Sodium and fluid balance, potassium status and renal function are all under active pharmacological management, which narrows the margin available to anything taken alongside it.

Common Symptoms

Dyspnea (exertional and at rest) Orthopnea Paroxysmal nocturnal dyspnea Peripheral edema Fatigue Exercise intolerance

Risk Factors

  • Coronary artery disease
  • Hypertension
  • Diabetes
  • Valvular disease
  • Prior myocardial infarction
  • Obesity
  • Excessive alcohol

Frequently Asked Questions

What supplements may help with Heart Failure?
Based on peer-reviewed research, supplements with the strongest evidence for Heart Failure include Coenzyme Q10 (CoQ10), Hawthorn. These have earned Grade A or B ratings from our analysis of clinical studies. Always consult your healthcare provider before starting any supplement.
How is the evidence for Heart Failure supplements graded?
We grade supplements on an A-F scale based on clinical study quality, consistency of results, sample sizes, and study design. Grade A indicates strong evidence from multiple clinical trials, while Grade D indicates preliminary evidence requiring further research.
How many studies on Heart Failure supplements have been reviewed?
Our evidence grades for Heart Failure are based on a total of 42 peer-reviewed studies across 7 ingredients. Studies are sourced from PubMed and include randomized controlled trials, meta-analyses, and other clinical research.
What are common symptoms of Heart Failure?
Common symptoms associated with Heart Failure include Dyspnea (exertional and at rest), Orthopnea, Paroxysmal nocturnal dyspnea, Peripheral edema, Fatigue. If you are experiencing these symptoms, consult a healthcare professional for proper diagnosis and treatment options.

References

  1. 1. Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. Circulation. Heart failure, 2016 PMID 27012265
  2. 2. Coenzyme Q10 and Utility in Heart Failure: Just Another Supplement? Current heart failure reports, 2016 PMID 27333901
  3. 3. Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality. Current cardiology reports, 2023 PMID 37971634
  4. 4. Vitamins in Heart Failure: Friend or Enemy? Current pharmaceutical design, 2017 PMID 28325140

Condições que partilham ingredientes estudados

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.